Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist.
Campbell
R Keith
RK
Washington State University, USA.
Neumiller
Joshua J
JJ
White
John
J
Sisson
Evan
E
Kuhn
Catherine
C
D001291:Attitude of Health Personnel; D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D054795:Incretins / Q000378:metabolism; D010353:Patient Education as Topic; D010595:Pharmacists; D024382:Professional Role; D018027:Receptors, Glucagon / Q000819:agonists; D016896:Treatment Outcome
D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D054795:Incretins; D018027:Receptors, Glucagon; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4